+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Orexo AB - logo

Orexo AB is a specialty pharmaceutical company in the United States. Its launched products include Zubsolv sublingual tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, an active substance zolpidem that is used for the treatment of short-term insomnia. It has collaboration agreement with Mundipharma for the development and commercialization of Zubsolv and with AstraZeneca with regards to the OX-Cysteinyl Leukotriene Inhibitor project. Founded in 1995, the company is headquartered in Uppsala, Sweden.

Opioid Use Disorder - Global Strategic Business Report - Product Thumbnail Image

Opioid Use Disorder - Global Strategic Business Report

  • Report
  • June 2025
  • 177 Pages
  • Global
From
Opioid Use Disorder (OUD) Market Report 2025 - Product Thumbnail Image

Opioid Use Disorder (OUD) Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Cyclo-oxygenase 2 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Cyclo-oxygenase 2 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 90 Pages
  • Global
From
From
Naloxone - Global Strategic Business Report - Product Thumbnail Image

Naloxone - Global Strategic Business Report

  • Report
  • June 2025
  • 369 Pages
  • Global
From
Licensing Deals in Pharmaceuticals 2019-2025 - Product Thumbnail Image

Licensing Deals in Pharmaceuticals 2019-2025

  • Report
  • April 2025
  • 1400 Pages
  • Global
From
Epinephrine Market Report 2025 - Product Thumbnail Image

Epinephrine Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
From
Gastroparesis Market Report 2025 - Product Thumbnail Image

Gastroparesis Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
Loading Indicator